|
|||||
|
|
Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries |
|
| Authors: | Hideki Maeda Tatsuo Kurokawa |
| Affiliation: | 1. Drug Development and Regulatory Science, Graduate School of Pharmaceutical Sciences, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan 2. Oncology, Clinical Development Department, Development, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |